statistiche ricercatore

Continente	#
NA - Nord America	876
AS - Asia	295
EU - Europa	258
Continente sconosciuto - Info sul continente non disponibili	81
SA - Sud America	78
AF - Africa	20
Totale	1.608

Nazione	#
US - Stati Uniti d'America	866
SG - Singapore	104
IT - Italia	76
CN - Cina	70
BR - Brasile	62
HK - Hong Kong	42
RU - Federazione Russa	40
SE - Svezia	39
DE - Germania	26
VN - Vietnam	25
GB - Regno Unito	19
FR - Francia	17
FI - Finlandia	13
IN - India	10
AR - Argentina	8
CA - Canada	8
CI - Costa d'Avorio	8
BD - Bangladesh	7
JP - Giappone	6
PH - Filippine	6
IQ - Iraq	5
NL - Olanda	5
BE - Belgio	4
ID - Indonesia	4
CO - Colombia	3
EC - Ecuador	3
ES - Italia	3
SA - Arabia Saudita	3
UZ - Uzbekistan	3
ZA - Sudafrica	3
AT - Austria	2
ET - Etiopia	2
GA - Gabon	2
LT - Lituania	2
PK - Pakistan	2
RS - Serbia	2
TR - Turchia	2
UA - Ucraina	2
AE - Emirati Arabi Uniti	1
AL - Albania	1
AZ - Azerbaigian	1
BY - Bielorussia	1
CH - Svizzera	1
DK - Danimarca	1
DZ - Algeria	1
IE - Irlanda	1
IL - Israele	1
IR - Iran	1
JM - Giamaica	1
KE - Kenya	1
LA - Repubblica Popolare Democratica del Laos	1
LB - Libano	1
MA - Marocco	1
MX - Messico	1
PL - Polonia	1
PT - Portogallo	1
PY - Paraguay	1
RO - Romania	1
SN - Senegal	1
SO - Somalia	1
UY - Uruguay	1
Totale	1.527

Nome	#
Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging	224
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis	208
Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study	154
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study	150
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis	127
Detection of disability worsening in relapsing-remitting multiple sclerosis patients. A real-world roving EDSS-Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register	124
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study	118
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register	112
Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study	95
Isoelectric focusing and crossed immunoelectrofocusing of cerebrospinal fluid proteins in neurological disorders	95
null	74
null	65
null	44
null	18
Totale	1.608

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	87	0	0	6	2	6	10	4	7	5	8	17	22
2022/2023	143	18	23	13	6	17	23	1	15	22	0	3	2
2023/2024	72	2	10	7	17	10	13	1	1	1	2	1	7
2024/2025	249	13	3	14	15	3	22	24	23	30	7	40	55
2025/2026	500	94	17	31	43	60	31	40	13	75	41	21	34
2026/2027	45	13	16	16	0	0	0	0	0	0	0	0	0
Totale													1.608